Dapagliflozin in heart failure with preserved and mildly reduced ejection fraction: rationale and design of the DELIVER trial

AIMS: Sodium–glucose co‐transporter 2 (SGLT2) inhibitors, originally developed as glucose‐lowering agents, have been shown to reduce heart failure hospitalizations in patients with type 2 diabetes without established heart failure, and in patients with heart failure with and without diabetes. Their...

Descripción completa

Detalles Bibliográficos
Autores principales: Solomon, Scott D., de Boer, Rudolf A., DeMets, David, Hernandez, Adrian F., Inzucchi, Silvio E., Kosiborod, Mikhail N., Lam, Carolyn S.P., Martinez, Felipe, Shah, Sanjiv J., Lindholm, Daniel, Wilderäng, Ulrica, Öhrn, Fredrik, Claggett, Brian, Langkilde, Anna Maria, Petersson, Magnus, McMurray, John J.V.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley & Sons, Ltd. 2021
Materias:
Trial Designs
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361994/
https://www.ncbi.nlm.nih.gov/pubmed/34051124
http://dx.doi.org/10.1002/ejhf.2249

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8361994/
https://www.ncbi.nlm.nih.gov/pubmed/34051124
http://dx.doi.org/10.1002/ejhf.2249

Ejemplares similares